The CEO of the Healthcare Business of Merck KGaA, Belén Garijo, inaugurated a new lab-space exclusive of Merck.
The new facility will accommodate the expansion of the Merck Satellite lab, to the area of Assay Development enabling High-Throughput Screening of new drug candidates, as announced earlier this year by Merck KGaA.
This symbolic cerimony took place at iBET on October 11th and was presided by the CEO of the Healthcare Business of Merck KGaA, Belén Garijo, and the CEO of iBET, Paula Alves.
In addition to the inauguration of the new space, this event was an excellent opportunity to assess ongoing ventures and discuss future developments of Merck-iBET partnership.
Aside from Merck Satellite lab, iBET has been enrolled in multiple collaborative projects with Merck KGaA over the last 22 years. Ongoing research projects include:
- Production and purification of new proteins of clinical interest
- Development of new models to study compounds for malaria treatments
- Development of sustainable processes for vaccine production
- Identification and characterization of antibodies and antigen for oncotherapy
